Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity

Pharmacological Reports

Volumn 64, Issue 5, 2012, Pages 1234-1242

  Fidlerova, Julie ^a   Kleiblova, Petra ^a   Kormunda, Stanislav ^b   Novotny, Jan ^b   Kleibl, Zdenek ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

5 fluorouracil; Denaturing high performance liquid chromatography (DHPLC); Fluoropyrimidines; Toxicity; alanine synthase; ureidopropionase (UPB1)

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROPIONIC ACID;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG TOLERANCE; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HETEROZYGOTE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUTROPENIA; NUCLEOTIDE SEQUENCE; OROFACIAL CANCER; PANCREAS CANCER; PHARYNX CANCER; STOMACH CANCER; THROMBOCYTOPENIA; UPB1 GENE;

EID: 84873733230     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70919-2     Document Type: Article

References (23)

1. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 2004, 350, 2343-2351. (Pubitemid 38702845)
2. Assmann BE, van Kuilenburg AB, Distelmaier F, Abeling NG, Rosenbaum T, Schaper J, Duran M, Mayatepek E: β-Ureidopropionase deficiency presenting with febrile status epilepticus. Epilepsia, 2006, 47, 215-217.
3. Carter KW, McCaskie PA, Palmer LJ: JLIN: a java based linkage disequilibrium plotter. BMC Bioinformatics, 2006, 7, 60.
4. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C: Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer, 2010, 9, 224-228.
5. Fidlerova J, Kleiblova P, Bilek M, Kormunda S, Formankova Z, Novotny J, Kleibl Z: Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients. Cancer Chemother Pharmacol, 2010, 65, 661-669.
6. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML et al.: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol, 2006, 24, 4085-4091. (Pubitemid 46622283)
7. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L et al.: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol, 2008, 26, 3523-3529.
8. Hsiao HH, Lin SF: Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency. Curr Pharmacogenomics, 2007, 5, 31-38.
9. Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, Sevcik J, Novotny J: Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma, 2009, 56, 303-316.
10. Kleiblova P, Dostalova I, Bartlova M, Lacinova Z, Ticha I, Krejci V, Springer D et al.: Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus. Mol Cell Endocrinol, 2010, 314, 150-156.
11. Kuhara T, Ohse M, Inoue Y, Shinka T: Five cases of beta-ureidopropionase deficiency detected by GC/MS analysis of urine metabolome. J Mass Spectrom, 2009, 44, 214-221.
12. Lundgren S, Lohkamp B, Andersen B, Piskur J, Dobritzsch D: The crystal structure of β-alanine synthase from Drosophila melanogaster reveals a homooctameric helical turnlike assembly. JMol Biol, 2008, 377, 1544-1559.
13. Ohse M, Matsuo M, Ishida A, Kuhara T: Screening and diagnosis of β-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine. J Mass Spectrom, 2002, 37, 954-962.
14. Scholzova E, Malik R, Sevcik J, Kleibl Z: RNA regulation and cancer development. Cancer Lett, 2007, 246, 12-23. (Pubitemid 44959406)
15. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R et al.: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol, 2008, 26, 2131-2138.
16. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB: Genetic regulation of β-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics, 2008, 18, 25-35. (Pubitemid 351161646)
17. Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z: Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity. Cancer Chemother Pharmacol, 2009, 64, 615-618.
18. van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer, 2004, 40, 939-950.
19. van Kuilenburg AB,Meinsma R, Assman B, Hoffman GF, Voit T, Ribes A, Lorente I et al.: Genetic analysis of the first 4 patients with β-ureidopropionase deficiency. Nucleosides Nucleotides Nucleic Acids, 2006, 25, 1093-1098. (Pubitemid 44651853)
20. van Kuilenburg AB, Meinsma R, Beke E, Assmann B, Ribes A, Lorente I, Busch R et al.: β-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum Mol Genet, 2004, 13, 2793-2801. (Pubitemid 39562543)
21. van Kuilenburg AB, van Lenthe H, van Gennip AH: Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids, 2006, 25, 1211-1214.
22. Vreken P, van Kuilenburg AB, Hamajima N, Meinsma R, van Lenthe H, Göhlich-Ratmann G, Assmann BE et al.: cDNAcloning, genomic structure and chromosomal localization of the human BUP-1 gene encoding β- ureidopropionase. Biochim Biophys Acta, 1999, 1447, 251-257. (Pubitemid 29494998)
23. Yaplito-Lee J, Pitt J, Meijer J, Zoetekouw L, Meinsma R, van Kuilenburg AB: β-Ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems. Mol Genet Metab, 2008, 93, 190-194.